SCHEMBL29609758

SCHEMBL29609758

Cc1cccc2cc(C(N)=O)[nH]c12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 3/20 0.60
HRH4 Q9H3N8 6/20 0.57
SMYD3 Q9H7B4 2/20 0.56
DAO P14920 1/20 0.54
DDO Q99489 1/20 0.54
SETD2 Q9BYW2 3/20 0.51
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 2/20 0.47
ALDH1A1 P00352 3/20 0.46
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
GLA P06280 1/20 0.44
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28399059 1.00 NSD2 (0.60) NSD2HRH4SMYD3DAODDO
SCHEMBL2042234 0.84 NSD2 (0.66) NSD2HRH4SMYD3DAODDO
SCHEMBL18354217 0.84 NSD2 (0.61) NSD2HRH4SMYD3DAODDO
SCHEMBL25139601 0.80 NSD2 (0.57) NSD2HRH4SMYD3DAODDO
SCHEMBL3283667 0.80 NSD2 (0.61) NSD2HRH4SMYD3DAODDO
SCHEMBL7884356 0.79 NSD2 (0.50) NSD2HRH4SMYD3DAODDO
SCHEMBL7942068 0.79 HRH4 (0.57) HRH4DAODDOHSD17B10ALDH1A1
SCHEMBL29063451 0.79 HRH4 (0.56) HRH4DAOKDM4EHSD17B10ALDH1A1
SCHEMBL30310556 0.79 HRH4 (0.56) HRH4DAOKDM4EHSD17B10ALDH1A1
SCHEMBL21739100 0.79 NSD2 (0.68) NSD2HRH4SMYD3DAODDO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099424-A1 Nitrile-Containing Antiviral Compounds PFIZER INC. (US) 2025-03-27 US disclosed
US-20240299352-A1 COMBINATION THERAPIES WITH SETD2 INHIBITORS Epizyme, Inc. 2024-09-12 US disclosed
US-20230133671-A1 SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES Epizyme, Inc. (US) 2023-05-04 US disclosed
US-20230120254-A1 Nitrile-Containing Antiviral Compounds PFIZER INC. (US) 2023-04-20 US disclosed
US-11452711-B2 Nitrile-containing antiviral compounds PFIZER INC. (US) 2022-09-27 US disclosed
US-20220257563-A1 Nitrile-Containing Antiviral Compounds PFIZER INC. (US) 2022-08-18 US disclosed
US-11351149-B2 Nitrile-containing antiviral compounds PFIZER INC. (US) 2022-06-07 US disclosed
US-20220142976-A1 Nitrile-Containing Antiviral Compounds PFIZER INC. (US) 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220257563-A1 Nitrile-Containing Antiviral Compounds ACE2, NOS2, EIF2AK2 NSD2 60/4885HRH4 3235/4885SMYD3 2065/4885
US-11452711-B2 Nitrile-containing antiviral compounds ACE2, NOS2, EIF2AK2 NSD2 60/4885HRH4 3235/4885SMYD3 2065/4885
US-20230120254-A1 Nitrile-Containing Antiviral Compounds ACE2, NOS2, EIF2AK2 NSD2 60/4885HRH4 3235/4885SMYD3 2065/4885
US-20250099424-A1 Nitrile-Containing Antiviral Compounds ACE2, NOS2, EIF2AK2 NSD2 60/4885HRH4 3235/4885SMYD3 2065/4885
US-20220142976-A1 Nitrile-Containing Antiviral Compounds ACE2, NOS2, EIF2AK2 NSD2 60/4885HRH4 3235/4885SMYD3 2065/4885
US-20240299352-A1 COMBINATION THERAPIES WITH SETD2 INHIBITORS SETD2, CARM1, SETDB1 NSD2 35/4885HRH4 4351/4885SMYD3 386/4885
US-11351149-B2 Nitrile-containing antiviral compounds ACE2, NOS2, EIF2AK2 NSD2 60/4885HRH4 3235/4885SMYD3 2065/4885
US-20230133671-A1 SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES EZH2, HDAC2, SETD2 NSD2 14/4885HRH4 3102/4885SMYD3 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.